Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Regulators Report Steady Progress In Promoting Innovation - DIA China Conference

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's State FDA has made steady progress in meeting the challenges of drug supervision while at the same time encouraging innovation and ensuring safety, SFDA Deputy Commissioner Wu Zhen told executives and scientists during the second Drug Information Association China annual meeting in Beijing this week

You may also be interested in...



China's Sinovac Just Steps Away From Crossing Global Finish Line In Race To Launch A/H1N1 Vaccine

BEIJING - Just days away from widely expected regulatory approval for an A/H1N1 vaccine, the Beijing-based Sinovac Biotech is now virtually guaranteed to become the first producer in the world to market a defense to the swine flu pandemic

China To Step Up Supervision Of APIs And Drug Excipients – PDA-FDA Supply Chain Conference

SHANGHAI - China's State FDA is planning to launch a drug master file system to establish better controls for active pharmaceutical ingredients and drug excipients

China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference

SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel